Congratulations to the Volumetric team on their acquisition by 3D Systems!
Continue Reading >Invest in Eysz to accelerate personalized treatments with improved patient outcomes for 70M+ epilepsy patients worldwide.
Continue Reading >Congratulations to our portfolio company Echo on their acquisition by CELLINK!
Continue Reading >Watch our CEO, Neil Littman, share the story that inspired him to found Bioverge.
Continue Reading >The Bioverge Reg CF Offering is Officially Live 🎊 and Accepting Investments!
Continue Reading >Even in our modern age of medical miracles, the prognosis and treatments for end-stage organ failure are still woefully inadequate. IVIVA Medical is on course to change all that.
Continue Reading >Over 23 million Americans suffer from disorders that stem from their immune systems mistakenly attacking their own, healthy cells. Octagon offers revolutionary treatments for these autoimmune diseases without compromising healthy immune function.
Continue Reading >EnClear Therapies is developing device-based systems to reduce or stop the progression of neurodegenerative diseases by eliminating the toxic proteins that provoke these conditions.
Continue Reading >The desire to prolong life and youthful vigor has existed for centuries without uniformly tangible results. Repair Biotechnologies offers to transform this desire into a reality.
Continue Reading >Ancilia is a computational bio-platform company that engineers phage-resistant bacterial therapeutics utilizing CRISPR/Cas to treat microbiome-linked diseases including inflammatory bowel disease (IBD) and immunotherapy-associated colitis.
Continue Reading >